Literature DB >> 26807366

Mean apparent diffusion coefficient values in defining radiotherapy planning target volumes in glioblastoma.

Daniel Jeong1, Christian Malalis1, John A Arrington1, Aaron S Field1, Jung W Choi1, Mehmet Kocak1.   

Abstract

BACKGROUND: To evaluate mean apparent diffusion coefficient (ADC) values on pre-radiotherapy magnetic resonance (MR) at sites that gave rise to glioblastoma (GBM) recurrence compared to similar surrounding background tissue that did not progress to tumor.
METHODS: Twenty out of 110 consecutive patients with pathology proven GBM treated at our institution from 1/1/2009 to 5/31/2012 had definitive recurrence 6 months following radiotherapy. In this single-center retrospective cohort study, pre- and post-radiotherapy MR brain exams were evaluated. Sites of tumor recurrence on post-therapy exams were co-localized to pre-therapy exams and the background tissue type which gave rise to tumor was noted (i.e., T2 hyperintensity, normal appearing white or gray matter). Similar surrounding background tissue not progressing to tumor was also selected. Two radiologists compared mean ADC values on pre-radiotherapy MR for sites which gave rise to future tumor recurrence and sites of similar background tissue.
RESULTS: Pre-radiotherapy mean ADC values were significantly lower in regions of future tumor recurrence than in regions of surrounding background tissue not progressing to tumor (P=0.003). There were no significant quantitative differences on T1-weighted pre contrast (P=0.50) or T2-weighted (P=0.10) sequences between sites. There was strong interobserver agreement with an intraclass correlation of 0.867 for ADC values at sites of future tumor recurrence and background tissue.
CONCLUSIONS: Mean ADC values may help predict sites of future gross tumor recurrence in GBM, which could be helpful in radiation therapy planning.

Entities:  

Keywords:  Apparent diffusion coefficient (ADC); glioblastoma (GBM); magnetic resonance (MR); tumor recurrence

Year:  2015        PMID: 26807366      PMCID: PMC4700247          DOI: 10.3978/j.issn.2223-4292.2015.12.05

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  31 in total

Review 1.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

2.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.

Authors:  Andrew Elson; Eric Paulson; Joseph Bovi; Malika Siker; Chris Schultz; Peter S Laviolette
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

4.  Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients.

Authors:  Carles Majós; Mònica Cos; Sara Castañer; Miguel Gil; Gerard Plans; Anna Lucas; Jordi Bruna; Carles Aguilera
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

5.  Distinguishing recurrent primary brain tumor from radiation injury: a preliminary study using a susceptibility-weighted MR imaging-guided apparent diffusion coefficient analysis strategy.

Authors:  A Al Sayyari; R Buckley; C McHenery; K Pannek; A Coulthard; S Rose
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-28       Impact factor: 3.825

6.  MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms.

Authors:  David L Morse; Jean-Philippe Galons; Claire M Payne; Dominique L Jennings; Sam Day; Guowei Xia; Robert J Gillies
Journal:  NMR Biomed       Date:  2007-10       Impact factor: 4.044

7.  Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Authors:  Orin Bloch; Seunggu J Han; Soonmee Cha; Matthew Z Sun; Manish K Aghi; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2012-10-05       Impact factor: 5.115

8.  Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

Authors:  Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt
Journal:  Radiology       Date:  2012-11-30       Impact factor: 11.105

Review 9.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Authors:  B M Ellingson; S Sahebjam; H J Kim; W B Pope; R J Harris; D C Woodworth; A Lai; P L Nghiemphu; W P Mason; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2013-10-17       Impact factor: 3.825

View more
  2 in total

1.  The radiosurgery fractionation quandary: single fraction or hypofractionation?

Authors:  John P Kirkpatrick; Scott G Soltys; Simon S Lo; Kathryn Beal; Dennis C Shrieve; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 2.  Variability and Standardization of Quantitative Imaging: Monoparametric to Multiparametric Quantification, Radiomics, and Artificial Intelligence.

Authors:  Akifumi Hagiwara; Shohei Fujita; Yoshiharu Ohno; Shigeki Aoki
Journal:  Invest Radiol       Date:  2020-09       Impact factor: 10.065

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.